TY - JOUR
T1 - Celiac disease
T2 - New therapies on the horizon
AU - Dieckman, Tessa
AU - Koning, Frits
AU - Bouma, Gerd
N1 - Funding Information:
This research was supported by KWF Dutch Cancer Society (KWF, grant: UL 2015-2850 ) and by the collaboration project TIMID (LSHM18057-SGF), financed by the public-private partnership (PPP) allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfonden (SGF), to stimulate public-private partnerships and co-financing by health foundations that are part of the SGF. Figure 1 was created with BioRender.com .
Publisher Copyright:
© 2022 The Authors
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Celiac Disease (CeD) is a chronic intestinal disease which occurs in 0.7–1.4% of the global population. Since the discovery of gluten as its disease-inducing antigen, CeD patients are treated with a gluten-free diet which is effective but has limitations for certain groups of patients. Accordingly, over the past few years, there is a growing interest in alternative treatment options. This review summarizes emerging pharmacological approaches, including tolerance induction strategies, tissue transglutaminase inhibition, gluten degradation, and inhibition of interleukin (IL)-15.
AB - Celiac Disease (CeD) is a chronic intestinal disease which occurs in 0.7–1.4% of the global population. Since the discovery of gluten as its disease-inducing antigen, CeD patients are treated with a gluten-free diet which is effective but has limitations for certain groups of patients. Accordingly, over the past few years, there is a growing interest in alternative treatment options. This review summarizes emerging pharmacological approaches, including tolerance induction strategies, tissue transglutaminase inhibition, gluten degradation, and inhibition of interleukin (IL)-15.
UR - https://www.scopus.com/pages/publications/85135520540
U2 - 10.1016/j.coph.2022.102268
DO - 10.1016/j.coph.2022.102268
M3 - Review article
C2 - 35921776
SN - 1471-4892
VL - 66
JO - Current opinion in pharmacology
JF - Current opinion in pharmacology
M1 - 102268
ER -